Echinococcus granulosus infection: clinical presentation, medical treatment and outcome

Kern, Peter

doi:10.1007/s00423-003-0418-y

Cited by 114 publications

(108 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Echinococcus is not excluded by negative serology, late echinoccocal cysts may appear partly solid, or partially or fully calcified, displaying a similar morphology as in our case [8]. In late or inactive echinococcal cysts, antihelminthic treatment is not indicated, and the decision for a surgical option is guided by symptoms of the patients [8]. Diagnosis of peritoneal tuberculosis is less straightforward because the radiological morphology is unspecific [2,7].…”

Section: Discussionmentioning

confidence: 84%

Abdominal Tuberculosis: a Benign Differential Diagnosis for Peritoneal Carcinosis: Report of a Case

Schweinfurth¹

2014

Mycobact Dis

View full text Add to dashboard Cite

Tuberculosis remains a challenge in medicine despite availability of antibiotic treatments. Latent tuberculosis is found in a third of the world's population. Abdominal tuberculosis is a rare condition in high-income countries, with peritoneal tuberculosis and splenic abscess occurring even less frequently, even in countries with higher prevalence of abdominal tuberculosis. We describe such an uncommon constellation of peritoneal tuberculosis and splenic abscess. Our case demonstrates the challenges in diagnosing abdominal tuberculosis, providing the caveat that tuberculosis should be kept in mind whenever unspecific findings occur in abdominal imaging or unusual surgical findings. In our case, thorough history-taking -including explicit questionings about tuberculosis exposition decades ago -provided the only lead pointing towards the correct interpretation of otherwise unspecific findings. In our case, tuberculosis as a differential diagnosis to peritoneal carcinosis was only implied after histopathological evaluation, followed by timely diagnostics for pulmonary involvement and potential infectiousness.

show abstract

Section: Discussionmentioning

confidence: 84%

Abdominal Tuberculosis: a Benign Differential Diagnosis for Peritoneal Carcinosis: Report of a Case

Schweinfurth¹

2014

Mycobact Dis

View full text Add to dashboard Cite

show abstract

“…Traditionally, the treatment of echinococcosis relies primarily on surgery and/or chemotherapy, and the treatment strategy depends largely on different factors, such as metacestode size and location, viability status, the interaction between the expanding parasite and the adjacent host tissue, complicating bacterial or fungal infection and potential complications related to cyst rupture and spillage of protoscoleces (Kern, 2003(Kern, , 2006.…”

Section: I M I T a T I O N S O F C U R R E N T C H E M O T H E R A mentioning

confidence: 99%

“…A study comprised of 3282 echinococcosis patients treated with ABZ showed that most side-effects were associated with the gastrointestinal tract (Pawloski, 1997 ;Kern, 2003), but no fatal cases involving ABZ therapy have been described. In 3 .…”

Section: I M I T a T I O N S O F C U R R E N T C H E M O T H E R A mentioning

confidence: 99%

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

et al. 2007

View full text Add to dashboard Cite

Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of which the metacestode (larval) stages cause the diseases cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. Albendazole and mebendazole are presently used for chemotherapeutical treatment. However, these benzimidazoles do not appear to be parasiticidal in vivo against AE. In addition, failures in drug treatments as well as the occurrence of side-effects have been reported. New drugs are needed to cure AE and CE, which are considered to be neglected diseases. Strategies currently being implemented to identify novel chemotherapeutical treatment options include (i) conventional primary in vitro testing of broad-spectrum anti-infective drugs, either in parallel with, or followed by, animal experimentation ; (ii) studies of drugs which interfere with the proliferation of cancer cells and of Echinococcus metacestodes ; (iii) exploitation of the similarities between the parasite and mammalian signalling machineries, with a special focus on targeting specific signalling receptors ; (iv) in silico approaches, employing the current Echinococcus genomic database information to search for suitable targets for compounds with known modes of action. In the present article, we review the efforts toward obtaining better anti-parasitic compounds which have been undertaken to improve chemotherapeutical treatment of echinococcosis, and summarize the achievements in the field of host-parasite interactions which may also lead to new immuno-therapeutical options.

show abstract

“…For many years, the preferred treatment strategy for CE has been radical resection of the parasite mass (Kern, 2003(Kern, , 2006. Other options include imageguide percutaneous treatment (PAIR=puncture, aspiration, injection, reaspiration) (Brunetti et al 2004) and chemotherapy (El-On, 2002).…”

Section: E C H I N O C O C C U S: B I O L O G Y a N D D I S E A S Ementioning

confidence: 99%

Echinococcusmetacestodes as laboratory models for the screening of drugs against cestodes and trematodes

Hemphill¹,

Lundström‐Stadelmann²,

Scholl³

et al. 2009

Parasitology

View full text Add to dashboard Cite

Among the cestodes, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium represent the most dangerous parasites. Their larval stages cause the diseases cystic echinococcosis (CE), alveolar echincoccosis (AE) and cysticercosis, respectively, which exhibit considerable medical and veterinary health concerns with a profound economic impact. Others caused by other cestodes, such as species of the genera Mesocestoides and Hymenolepis, are relatively rare in humans. In this review, we will focus on E. granulosus and E. multilocularis metacestode laboratory models and will review the use of these models in the search for novel drugs that could be employed for chemotherapeutic treatment of echinococcosis. Clearly, improved therapeutic drugs are needed for the treatment of AE and CE, and this can only be achieved through the development of medium-to-high throughput screening approaches. The most recent achievements in the in vitro culture and genetic manipulation of E. multilocularis cells and metacestodes, and the accessability of the E. multilocularis genome and EST sequence information, have rendered the E. multilocularis model uniquely suited for studies on drug-efficacy and drug target identification. This could lead to the development of novel compounds for the use in chemotherapy against echinococcosis, and possibly against diseases caused by other cestodes, and potentially also trematodes.

show abstract

Echinococcus granulosus infection: clinical presentation, medical treatment and outcome

Cited by 114 publications

References 28 publications

Abdominal Tuberculosis: a Benign Differential Diagnosis for Peritoneal Carcinosis: Report of a Case

Abdominal Tuberculosis: a Benign Differential Diagnosis for Peritoneal Carcinosis: Report of a Case

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

Echinococcusmetacestodes as laboratory models for the screening of drugs against cestodes and trematodes

Contact Info

Product

Resources

About